Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists

Neurol Sci. 2020 Nov;41(11):3361-3363. doi: 10.1007/s10072-020-04501-7. Epub 2020 Jun 6.

Authors

Marina Picillo¹, Vincenzo Canoro², Giulio Cicarelli³, Roberto Erro², Paolo Barone²

Affiliations

¹ Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Neuroscience section, University of Salerno, Via Allende, 84084, Baronissi, SA, Italy. mpicillo@unisa.it.
² Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Neuroscience section, University of Salerno, Via Allende, 84084, Baronissi, SA, Italy.
³ Neurology Unit, S.G. Moscati Hospital, Avellino, Italy.

PMID: 32506356
DOI: 10.1007/s10072-020-04501-7

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiparkinson Agents / adverse effects
Carbidopa / adverse effects
Dopamine Agonists / adverse effects
Drug Combinations
Gels
Humans
Hyponatremia*
Levodopa / adverse effects
Parkinson Disease* / complications
Parkinson Disease* / drug therapy

Substances

Antiparkinson Agents
Dopamine Agonists
Drug Combinations
Gels
Levodopa
Carbidopa